Last reviewed · How we verify
Intravenous ketoprofen
Intravenous ketoprofen, marketed by Centre Hospitalier Universitaire de Nīmes, holds a position in the pain management segment. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk lies in the potential for increased competition post-patent expiry.
At a glance
| Generic name | Intravenous ketoprofen |
|---|---|
| Also known as | Nonsteroidal anti-inflammatory drug |
| Sponsor | Centre Hospitalier Universitaire de Nīmes |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ketamine Administration for Postoperative Pain Management in Patients Undergoing Knee Arthroplasty (NA)
- Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes (NA)
- Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room (PHASE3)
- Non-steroidal Anti-inflammatory in Cardiac Surgery (PHASE3)
- Non-steroidal Anti-inflammatory Drugs in Pleurodesis (PHASE2)
- Quadratus Lumborum Block for Total Abdominal Hysterectomy (NA)
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- Comparison of Two Pain-treatment Techniques After Cesarean Section (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |